Bridgeway Capital Management, LLC Chemo Centryx, Inc. Transaction History

Bridgeway Capital Management, LLC

$4.14 Billion
Q2 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2018 Feb 14, 2019	SELL	$9.15 - $12.26 $163,748 - $219,404	-17,896 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$10.49 - $13.72 $157,350 - $205,800	-15,000 Reduced 45.6%	17,896 $226,000
Q2 2018 Aug 14, 2018	SELL	$10.62 - $13.98 $184,257 - $242,553	-17,350 Reduced 34.53%	32,896 $433,000
Q1 2018 May 15, 2018	SELL	$5.9 - $14.99 $12,685 - $32,228	-2,150 Reduced 4.1%	50,246 $683,000
Q4 2017 Feb 14, 2018	SELL	$5.53 - $8.42 $3,594 - $5,473	-650 Reduced 1.23%	52,396 $312,000
Q3 2017 Nov 14, 2017	BUY	$6.5 - $10.69 $344,799 - $567,061	53,046	53,046 $394,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.